At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 30 enrolled
Drug / intervention
Escitalopramdrug
Likely dose
Escitalopram 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Escitalopram in Patients With Social Anxiety Disorder; Open-label, One Arm Postmarketing Study in Russia
In Brief
A Phase 4 clinical trial evaluating Escitalopram for Social Anxiety Disorder. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the effect of escitalopram after 12 weeks of treatment in patients with Social Anxiety Disorder (SAD), to evaluate proportion of patients who respond to escitalopram during the treatment period, and to evaluate safety of escitalopram.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSocial Anxiety Disorder
CountriesRussia
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2009
First PostedMay 2009
Primary CompletionDec 2009
Study CompletionMar 2010
TodayJul 2026
First PostedMay 15, 2009
Enrollment StartMar 1, 2009
Primary CompletionDec 1, 2009
Study CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 17.1 years ago
Interventions
Escitalopramdrug
Flexible-dosed (5 to 20 mg Oral Tablets Daily)